CLAIMS

1. A crystal of lipocalin-type prostaglandin D synthase derived from mouse.

2. A crystal as claimed in Claim 1 which has orthorhombic system space group $P2_12_12_1$ and in which the size of unit cell is a=46.2±0.5Å, b=66.8±0.7Å, and c=105.3±1.0Å

3. A crystal as claimed in Claim 1 which has orthorhombic system space group $C222_1$ and in which the size of unit cell is a=45.7±0.5Å, b=66.8±0.7Å, and c=104.5±1.0Å.

4. Lipocalin-type prostaglandin D synthase having a three dimensional structure represented by the structural coordinates in Table 2.

5. Lipocalin-type prostaglandin D synthase having a three dimensional structure represented by the structural coordinates in Table 3.

6. Use of the structural coordinates in Table 2 or 3 for the selection of a compound which inhibits lipocalin-type prostaglandin D synthase.

7. A method for selecting an inhibitor of lipocalin-type prostaglandin D synthase, which comprising

(a) providing the three dimensional structure coordinates in Table 2 or 3 representing three dimensional structure of lipocalin-type prostaglandin D synthase;

(b) providing three dimensional structures of

candidate compounds; and

(c) selecting the candidate compound which fits to the substrate-binding site of lipocalin-type prostaglandin D synthase as inhibitor.

8. A method as claimed in Claim 7, further comprising (d) contacting the inhibitor as selected above with lipocalin-type prostaglandin D synthase in the presence of prostaglandin H_2 to measure L-PGDS enzyme activity to confirm the inhibiting effect of the inhibitor selected.

9. An inhibitor for lipocalin-type prostaglandin D synthase selected by the method of Claim 7 or 8.

10. An inhibitor for lipocalin-type prostaglandin D synthase which is 4-dibenzo(a,d)cyclohepten-5-ylidene-1-(4-(2H-tetrazole-5-yl)butyl)piperidine.